ATE537189T1 - Anti-tfr-antikörper - Google Patents

Anti-tfr-antikörper

Info

Publication number
ATE537189T1
ATE537189T1 AT04762981T AT04762981T ATE537189T1 AT E537189 T1 ATE537189 T1 AT E537189T1 AT 04762981 T AT04762981 T AT 04762981T AT 04762981 T AT04762981 T AT 04762981T AT E537189 T1 ATE537189 T1 AT E537189T1
Authority
AT
Austria
Prior art keywords
tfr antibodies
antibody
tfr
antibodies
relates
Prior art date
Application number
AT04762981T
Other languages
English (en)
Inventor
Renato Monteiro
Olivier Hermine
Ivan Moura
Yves Lepelletier
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE537189T1 publication Critical patent/ATE537189T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04762981T 2004-04-30 2004-04-30 Anti-tfr-antikörper ATE537189T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2004/005744 WO2005111082A1 (en) 2004-04-30 2004-04-30 Anti-tfr antibody.

Publications (1)

Publication Number Publication Date
ATE537189T1 true ATE537189T1 (de) 2011-12-15

Family

ID=34958155

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762981T ATE537189T1 (de) 2004-04-30 2004-04-30 Anti-tfr-antikörper

Country Status (8)

Country Link
US (1) US7976841B2 (de)
EP (1) EP1740616B1 (de)
AT (1) ATE537189T1 (de)
DK (1) DK1740616T3 (de)
ES (1) ES2379526T3 (de)
PL (1) PL1740616T3 (de)
PT (1) PT1740616E (de)
WO (1) WO2005111082A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Ｉｌ－１７結合蛋白
EP2453892B1 (de) * 2009-07-16 2013-05-29 Institut National de la Santé et de la Recherche Medicale Pharmazeutische zusammensetzungen und deren verwendung zur krebstherapie
AR081246A1 (es) 2010-05-14 2012-07-18 Abbott Lab Proteinas de union a il-1
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (de) 2010-08-03 2018-03-14 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne und verwendungen davon
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
PE20141060A1 (es) 2010-12-21 2014-09-26 Abbvie Inc Inmunoglobulinas de dominio variable dual biespecificas de il-1 alfa y beta y su uso
RU2013150331A (ru) * 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
CA2835603A1 (en) 2011-05-09 2012-11-15 Perseus Proteomics Inc. Antibody capable of specifically recognizing transferrin receptor
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
TWI450727B (zh) 2011-12-29 2014-09-01 財團法人工業技術研究院 抗人類輸鐵蛋白受體的單域抗體與其應用
EP2859017B1 (de) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
UY34905A (es) 2012-07-12 2014-01-31 Abbvie Inc Proteínas de unión a il-1
WO2014020140A1 (en) 2012-08-02 2014-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of transferrin receptor antagonist for the treatment of thalassemia
EP2890402B1 (de) 2012-08-31 2019-04-17 Sutro Biopharma, Inc. Modifizierte aminosäuren mit einer azidogruppe
CA2893794C (en) 2012-11-08 2021-11-09 University Of Miyazaki Antibody capable of specifically recognizing transferrin receptor
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
EP2971047A4 (de) * 2013-03-15 2016-11-30 Alper Biotech Llc Monoklonale antikörper gegen transferrin und transferrin-rezeptorantigene sowie verwendungen davon
EP3594240B1 (de) 2013-05-20 2023-12-06 F. Hoffmann-La Roche AG Anti-transferrin-rezeptor-antikörper und verfahren zur verwendung
US9499628B2 (en) * 2013-06-14 2016-11-22 Children's Hospital Medical Center Method of boosting the immune response in neonates
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
FI3218005T3 (fi) 2014-11-12 2023-03-31 Seagen Inc Glykaanin kanssa vuorovaikutteisia yhdisteitä ja käyttömenetelmiä
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US10508151B2 (en) 2014-11-19 2019-12-17 Genentech, Inc. Anti-transferrin receptor antibodies and methods of use
BR112017023862A2 (pt) 2015-05-04 2018-07-17 Cytomx Therapeutics Inc anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes
RU2737637C2 (ru) * 2015-07-22 2020-12-01 Инатерис Антитела против tfr и их применение при лечении пролиферативных и воспалительных расстройств
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018160909A1 (en) 2017-03-03 2018-09-07 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof
WO2019173771A1 (en) 2018-03-09 2019-09-12 Cytomx Therapeutics, Inc. Activatable cd147 antibodies and methods of making and use thereof
EP3552631A1 (de) 2018-04-10 2019-10-16 Inatherys Antikörper-arzneimittel-konjugate und deren verwendungen zur behandlung von krebs
US20210186880A1 (en) 2018-08-03 2021-06-24 Brown University Oral formulations with increased uptake
WO2020105621A1 (ja) 2018-11-20 2020-05-28 株式会社ペルセウスプロテオミクス 細胞内への鉄の取り込み阻害剤
JP7706210B2 (ja) 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
CN114746420A (zh) 2019-06-17 2022-07-12 苏特罗生物制药公司 用于癌症治疗和诊断的作为Toll样受体（TLR）7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物
EP4026560A4 (de) 2019-09-04 2023-10-25 Perseus Proteomics Inc. Therapeutisches mittel für polyzythämie
JP2022548310A (ja) 2019-09-23 2022-11-17 シートムエックス セラピューティクス，インコーポレイテッド 抗ｃｄ４７抗体、活性化可能抗ｃｄ４７抗体、およびその使用方法
US20230250180A1 (en) 2019-11-27 2023-08-10 Perseus Proteomics Inc. Therapeutic drug for carcinomatous peritonitis
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
MX2022012973A (es) 2020-04-26 2022-11-09 Biocytogen Pharmaceuticals Beijing Co Ltd Inmunoglobulinas modificadas.
WO2022000167A1 (zh) * 2020-06-29 2022-01-06 中国科学院昆明动物研究所 转铁蛋白、转铁蛋白受体及其抗体在制备抗SARS-CoV-2病毒的药物中的应用
US20240288453A1 (en) 2020-10-08 2024-08-29 National University Corporation Tokai National Higher Education And Research System Method for determining medicinal effect or sensitivity of anti-transferrin receptor antibody
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
JPWO2023027164A1 (de) 2021-08-26 2023-03-02
WO2023034409A1 (en) 2021-09-01 2023-03-09 Biogen Ma Inc. Anti-transferrin receptor antibodies and uses thereof
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
US20250263497A1 (en) 2022-04-19 2025-08-21 Tokai University Educational System Therapeutic agent for nk-cell tumor
AU2023301192A1 (en) 2022-06-27 2025-01-30 Sutro Biopharma, Inc. β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
CN119948030A (zh) 2022-07-15 2025-05-06 苏特罗生物制药公司 蛋白酶/酶可切割连接体-有效载荷及蛋白质偶联物
EP4477236A1 (de) 2023-06-14 2024-12-18 Inatherys Kombinationstherapie zur behandlung eines tumors mit adc mit anti-cd71-antikörpern und bh3-mimetika
AU2024299328A1 (en) 2023-07-21 2026-01-22 Marrow Therapeutics, Inc. Hematopoietic cell targeting conjugates and related methods
WO2025029832A2 (en) 2023-07-31 2025-02-06 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
WO2025080711A1 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Dual payload antibody drug conjugates
WO2025264647A1 (en) 2024-06-18 2025-12-26 Sutro Biopharma, Inc. Oxoadenine tlr7 agonist compounds and conjugates
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof
WO2026080692A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Branched beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
WO2026080697A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use
WO2026080688A1 (en) 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Dual mechanism of action payload antibody drug conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991014452A1 (en) * 1990-03-27 1991-10-03 The Salk Institute For Biological Studies Method for inhibiting cell growth and compositions useful therefor
DE69840340D1 (de) * 1997-12-19 2009-01-22 Asulab Sa Anzeigeeinheit mit zwei übereinander liegenden anzeigevorrichtungen
US6542146B1 (en) * 1999-05-27 2003-04-01 Lear Corporation Transparent electroluminescent display with mechanical gauge

Also Published As

Publication number Publication date
EP1740616A1 (de) 2007-01-10
ES2379526T3 (es) 2012-04-27
EP1740616B1 (de) 2011-12-14
PT1740616E (pt) 2012-03-23
US20080193453A1 (en) 2008-08-14
US7976841B2 (en) 2011-07-12
PL1740616T3 (pl) 2012-06-29
DK1740616T3 (da) 2012-03-26
WO2005111082A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
ATE537189T1 (de) Anti-tfr-antikörper
CY2023018I2 (el) Συνθεσεις αντισωματων anti-ctla-4
CY2021033I1 (el) Συνθεση αντισωματος ιντερλευκινης-13
IL272883A (en) Monoclonal antibodies and their uses
IS8596A (is) Mótefni gegn CD154
DK1771482T3 (da) HER2-antistofsammensætning
IL184152A0 (en) Monoclonal antibodies against nkg2a
DK1802344T3 (da) Antistofformulering i histidin-acetat-puffer.
DK1794586T3 (da) Monoklonale antistoffer til progastrin
LT3656793T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
SG10201404801YA (en) Monoclonal antibody
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EP1761566A4 (de) Humanisierte monoklonale anti-tag-72-antikörper
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
NO20071430L (no) Anti-OX4OL antistoffer
PL1850873T3 (pl) Przeciwciała przeciwko tgfbeta
HUS1500037I1 (hu) IL-17 antagonista antitestek
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
PL2177537T3 (pl) Przeciwciała przeciw MadCAM
EP2322562A4 (de) Monoklonaler antikörper und immunassay damit
ZA200706185B (en) Monoclonal antibodies against NKG2A
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
BRPI0509495A2 (pt) anticorpo humanizado
EP1712564A4 (de) Monoklonaler anti-nc1-antikörper